Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease

Next Previous
X
Search
Trial Profile

A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Neflamapimod (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Proof of concept; Therapeutic Use
  • Acronyms REVERSE-SD
  • Sponsors EIP Pharma

    • Most Recent Events

    • 06 Oct 2020 According to an EIP Pharma media release, results of this study were reported at the AAT-AD/PD Focus Meeting in April 2020.
    • 05 Dec 2019 Results published in EIP Pharma media release .
    • 05 Dec 2019 According to an EIP Pharma media release,Professor Philip Scheltens of the VU Medical Center in Amsterdam, Netherlands is a principal investigator of the study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top